Find information on thousands of medical conditions and prescription drugs.

Whooping cough

Pertussis, also known as "whooping cough," is a highly contagious disease that is one of the leading causes of vaccine-preventable deaths. There are 30–50 million cases per year, and about 300,000 deaths per year. Virtually all deaths occur in children under one year of age. Ninety percent of all cases occur in developing countries. It is caused by certain species of the bacterium Bordetella—usually B. pertussis, but some cases are caused by B. parapertussis. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
Panniculitis
Waardenburg syndrome
Wagner's disease
WAGR syndrome
Waldenstrom...
Wallerian degeneration
Warkany syndrome
Warts
Waterhouse-Friderichsen...
Watermelon stomach
Wegener's granulomatosis
Weissenbacher Zweymuller...
Werdnig-Hoffmann disease
Werner's syndrome
Whipple disease
Whooping cough
Willebrand disease
Willebrand disease, acquired
Williams syndrome
Wilms tumor-aniridia...
Wilms' tumor
Wilson's disease
Wiskott-Aldrich syndrome
Wolf-Hirschhorn syndrome
Wolff-Parkinson-White...
Wolfram syndrome
Wolman disease
Wooly hair syndrome
Worster-Drought syndrome
Writer's cramp
X
Y
Z
Medicines

The disease was recognizably described as early as 1578 by Guillaume de Baillou (1538-1616), but earlier reports date back at least to the 12th century. B. pertussis was isolated in pure culture in 1906 by Jules Bordet and Octave Gengou. The complete B. pertussis genome of 4,086,186 base pairs was sequenced in 2002.

Characterization

The disease is characterized initially by mild respiratory infection symptoms such as cough, sneezing, and runny nose. After one to two weeks the cough changes character, with paroxysms of coughing followed by an inspiratory "whooping" sound. Coughing fits may be followed by vomiting not necessarily due to nausea but due to the sheer violence of the fit itself, which in severe cases leads to malnutrition. The fits, that do occur on their own, can also be triggered by yawning, stretching, laughing, or yelling. Coughing fits gradually diminish over one to two months. Other complications of the disease include pneumonia, encephalitis, pulmonary hypertension, and secondary bacterial superinfection.

Transmission

The disease is spread by contact with airborne discharges from the mucous membranes of infected people. Laboratory diagnosis include; Calcium alginate throat swab, culture on Bordet-Gengou medium, immunofluorescence and serological methods. Treatment of the disease with antibiotics (often erythromycin, azithromycin, clarithromycin or trimethoprim-sulfamethoxazole) results in the person becoming less infectious but probably does not significantly alter the outcome of the disease. Close contacts who receive appropriate antibiotics, "chemoprophylaxis", during the 7–21 day incubation period may be protected from developing symptomatic disease.

Vaccines

Pertussis vaccines were initially formulated in 1926—most notable by Dr. Louis W. Sauer of Northwestern University and Evanston Hospital—as whole-cell preparations, but are now available as acellular preparations, which cause fewer side effects. They offer protection for only a few years, and are given so that immunity lasts through childhood, the time of greatest exposure and greatest risk. The immunizations are often given in combination with tetanus and diphtheria immunizations, at ages 2, 4, and 6 months, and later at 15–18 months and 4–6 years. Traditionally, pertussis vaccines are not given after age seven, as the frequency of side effects associated with the immunization tends to increase with age. The most serious side-effects of immunization are neurological: they include seizures and hypotonic episodes. An acellular vaccine preparation for older individuals is available in Canada and Europe, and two such products are being evaluated for their safety in adolescents and adults in the United States; a Food and Drug Administration decision was approved for use of the vaccine for 11-64 year olds in August 2005.

Read more at Wikipedia.org


[List your site here Free!]


New whooping cough vaccine
From FDA Consumer, 3/1/92

A new whooping cough vaccine licensed by FDA last Dec. 17 may cause fewer side effects in children.

"This vaccine may be very useful in getting more children protected," said James Mason, M.D., head of the Public Health Service and director of the National Vaccine Program. "Important as it has been in preventing a difficult and sometimes fatal disease, the old pertussis or whooping cough vaccine has caused more complaints of sore arms, fever, and occasionally more severe effects than most of the other childhood vaccines. As a result, some children never get their full series of shots."

The most common side effects reported in clinical trials of the new vaccine--brand name Acel-Imune--included tendemess, redness and swelling at the injection site, fever, drowsiness, fretfulness, and vomiting.

With diphtheria and tetanus components in addition to the pertussis vaccine, Acel-Imune is licensed for the fourth and fifth DTP shots; the old pertussis vaccine will continue to be used for the first three shots that constitute primary immunization. The new pertussis vaccine appears as effective as the old one in older children, and research is under way to determine its effectiveness in primary immunization in infants.

Whooping cough is so contagious it infects up to 90 percent of exposed household members who are not immune. Routine U.S. vaccination has brought a drop in case reports from 120,000 with 1,100 deaths in 1950 to an annual average in recent years of 3,500 with 10 deaths. However, in the wake of the largest U.S. measles outbreak in 20 years, with more than 27,600 cases and 89 deaths reported in 1990, the federal government is emphasizing early childhood immunizations. (See "A Responsibility to Remember: Childhood Vaccines" in the September 1990 FDA Consumer.)

The old pertussis vaccine is made from the whole pertussis organism, while the new one is made from only part of the organism and, thus, is called acellular. Availability of an acellular vaccine is a significant step forward in infectious disease control, said Gerald Quinnan, M.D., acting director of FDA's Center for Biologics, which evaluated and licensed Acel-Imune.

Takeda Chemical Industries Ltd. of Osaka, Japan, produces Acel-Imune's pertussis component, and Lederle Laboratories of Wayne, N.J., makes the diphtheria and tetanus portions and will distribute the product in the United States.

COPYRIGHT 1992 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group

Return to Whooping cough
Home Contact Resources Exchange Links ebay